Interactive Transcript
0:02
Hello, and welcome to Noon Conference hosted by Modality.
0:06
Noon Conference connects global radiology community through free live
0:10
educational webinars that are accessible for all and is an opportunity to learn
0:14
alongside top radiologists from around the world.
0:17
Today, we are honored to welcome Dr.
0:19
Omar Nemer
0:21
for a lecture entitled Benign and Malignant
0:24
Breast Calcifications.
0:27
Dr. Omar Nemer completed his radiology residency and breast imaging
0:31
fellowship at the University of Rochester Strong Memorial Hospital
0:35
in Rochester, New York. He returned to his birthplace of Northeast
0:39
Ohio, where he now serves as an associate program director of
0:43
diagnostic radiology at Case Western Reserve University
0:46
Hospitals. At the end of the lecture, please join Dr.
0:49
Nemer in a Q&A session where he will address questions you may have on today's
0:53
topic.
0:54
Please remember to use the Q&A feature to submit your questions so we can get to as
0:57
many as we can before our time is up.
1:00
With that, we are ready to begin today's lecture. Dr.
1:02
Nemer, please take it from here.
1:05
Hello, everyone. Thank you guys so much for joining me today.
1:08
I'm Omar Nemer, and I'm thrilled to be presenting you guys with a talk on
1:12
benign and malignant breast calcifications.
1:15
Calcifications remain one of the most challenging findings we encounter in breast
1:19
imaging. Although many of them represent a benign physiologic
1:22
process, others are the earliest and sometimes only
1:26
manifestation of breast cancer. Today, we'll review a practical
1:30
framework for interpreting calcifications using the updated
1:33
BI-RADS 6 lexicon while discussing the pathology and
1:37
clinical reasoning that guide management.
1:39
All cases used in this presentation are directly from our PAC system, unless
1:43
otherwise stated. No stock images were used in the making of this
1:47
presentation. There are a few AI-generated images, which I
1:51
will direct you guys to.
1:53
Please excuse the grayscale nature of this.
1:57
Color is often a luxury not afforded to us working in mammography.
2:03
I have nothing to disclose at this time.
2:07
And so what are exactly breast calcifications?
2:10
They're radiodense calcium deposits primarily composed of calcium
2:13
hydroxyapatite and calcium oxalate that occur in the breast
2:17
for a variety of benign and more concerning reasons.
2:22
So when do we identify calcifications?
2:25
They're initially detected on screening mammography in most cases.
2:30
After identifying the calcifications on a screening mammogram, the first thing we
2:34
need to ask ourselves is, are these clearly benign?
2:37
We'll discuss all the possible examples of typically benign
2:40
calcifications, for example, vascular and skin
2:43
calcifications. Next, if they're not clearly benign,
2:47
are they present on a prior mammogram?
2:50
If so, are they increasing, or are they stable?
2:53
If they're not clearly benign and have not been stable for ideally two
2:57
years, further workup should be recommended.
3:00
Things change a bit when we're working with a baseline exam, which we'll
3:04
discuss in more detail as well.
3:07
Finally, we should describe the location of the calcifications using the quadrant
3:10
of the breast in which they're seen and their depth and provide a
3:14
BI-RADS 0 assessment and recommend additional imaging with
3:17
diagnostic mammography. Annotation of the images is also
3:21
crucial to help future colleagues identify the exact area of
3:24
concern.
3:29
After we've identified the calcifications, the next step will almost
3:32
always be diagnostic mammography with spot magnification views in the
3:36
craniocaudal and mediolateral projections.
3:40
We need the mediolateral projection instead of an MLO view,
3:43
mediolateral oblique view, as these will most often
3:47
be targeted on either a CC or ML
3:51
projection. MLO biopsies are possible
3:55
but much more difficult.
3:58
For anyone interested in the underlying physics of a spot magnification view,
4:02
these are performed using an air gap for magnification with a tiny focal
4:05
spot for optimal resolution. Spot magnification
4:09
views should always be performed with attention to ensure there's no
4:12
motion, as it can significantly blur the morphology of the
4:15
calcifications. We then describe the location, the
4:19
morphology, the distribution, and the extent of the calcifications,
4:23
including measurements when appropriate for future extent of disease
4:26
discussions if the biopsies prove malignant.
4:31
Results for a diagnostic mammogram for calcifications can only be as follows.
4:36
BI-RADS 2 for benign calcifications, BI-RADS 3 for
4:39
probably benign calcifications, BI-RADS 4 for suspicious
4:43
calcifications, which would be anything greater than a 2%
4:46
chance of malignancy, and BI-RADS 5 for highly
4:50
suspicious calcifications or anything greater than a 95% chance of
4:54
malignancy.
4:58
This is an AI-generated slide provided to me by one of my
5:02
residents who did a fantastic job with this.
5:06
Before we discuss the morphology of calcifications, I'd like to discuss the
5:09
distribution.
5:11
Distribution describes how calcifications are arranged within the breast while the
5:15
morphology describes what each individual calcification looks like.
5:19
Morphology establishes the baseline level of suspicion, and the distribution
5:23
tells us whether the process appears random or follows the anatomy of the ductal
5:27
system.
5:28
Starting on the left, diffuse calcifications are scattered throughout a large
5:32
portion of the breast without a focal or ductal pattern.
5:35
When they are bilateral, symmetric, and have benign morphology, they're usually
5:39
benign. However, diffuse distribution does not override
5:43
suspicious morphology.
5:45
Regional calcifications occupy a relatively large volume,
5:49
generally greater than two centimeters, but do not conform to a duct or a
5:53
single breast segment. Malignancy is less likely than with
5:57
a linear or segmental pattern, although unilateral regional calcifications
6:01
with suspicious morphology should still require biopsy.
6:05
Grouped calcifications are concentrated in a small area of less than two
6:09
centimeters. Group distribution is not automatically suspicious
6:13
but often requires comparison with prior studies.
6:17
The key point is that grouping concentrates our attention,
6:21
but morphology determines what we'll do next.
6:24
Linear calcifications are arranged along a line, sometimes with branching.
6:29
This raises concern that the calcifications are depositing within a duct.
6:33
Suspicion increases considerably when the individual
6:36
calcifications are fine linear or fine linear branching.
6:39
And finally, segmental calcifications form a triangular or
6:43
wedge-shaped distribution pointing towards the nipple corresponding to a
6:47
duct in its branches within a breast segment.
6:50
When suspicious calcification morphology follows this pattern, the finding is
6:53
almost always associated with malignancy.
6:56
The take-home message is that distribution is not an absolute benign to malignant
7:00
scale. It's better understood as a risk modifier.
7:03
The final assessment should integrate morphology, distribution,
7:07
laterality, interval change, and associated findings such as a
7:11
mass or architectural distortion.
7:15
The first set of typically benign calcifications we'll discuss is skin
7:19
calcifications. These are often described as loose and centered, which
7:23
can overlap with other benign morphologies.
7:26
Although their appearance is often pathognomonic, these are even easier to
7:29
localize to the skin with the use of tomosynthesis rather than in the days of
7:33
traditional 2D mammography.
7:36
The classic teaching is that if calcifications are in the first or last five
7:39
slices of a tomosynthesis stack, they're likely to be within the skin.
7:43
I do find this to be a bit of an oversimplification.
7:46
Using the natural skin landmarks, such as observing the pores of the
7:50
skin or the skin vasculature, as we can see on our right-hand
7:54
image,
7:55
is a much more accurate depiction of whether they'll be
7:59
in the skin. The reason is that on the detector side of the
8:03
imaging, for example, on a craniocaudal view, the inferior aspect of the
8:07
breast would be against the detector.
8:09
The last image in the stack towards the caudal aspect of the
8:13
breast will always be at the skin. However, on the tube side of the
8:17
image, in this case in the superior aspect of the breast, the
8:20
tomosynthesis units can't exactly determine the slice where the
8:24
breast ends. So oftentimes, you'll have several tomosynthesis
8:27
slices which appear outside of the skin on the tube side of the stack.
8:31
So although you may be only in slice 50 out of 65,
8:36
you may still be well within the skin if you can see landmarks that clearly
8:39
identify the skin, such as the pores.
8:42
This is also very important when assessing breast calcifications along the
8:46
curvature of the breast.
8:49
So let's say you're stuck in ancient times with 2D mammography, or you're not quite
8:53
certain if those calcifications are in the skin on tomosynthesis
8:56
images. What options do we have to prove it?
9:00
That's where an old technique called tangential magnification views come
9:04
in. An image is taken of the breast with an alphanumeric grid
9:08
placed over the expected location of the calcifications.
9:11
Using the alphanumeric grid, a BB is placed over the site of the
9:14
calcifications. The breast is then rotated so that the BB is
9:18
tangential to the X-ray beam, and another image is taken.
9:22
If the calcifications are flush with the skin, you know they're skin calcs.
9:27
If the calcifications appear deeper, you know they're not.
9:30
There's one caveat. You need to be sure that you're on the correct side of the
9:33
breast. If the skin calcifications are inferior and you placed your BB
9:37
on the superior aspect of the breast, it's not going to work.
9:45
Next, let's discuss vascular calcifications.
9:47
These are often abbreviated BAC for breast arterial
9:50
calcifications, and they have their own grading system recently developed by
9:54
the Canadians from grade 0, meaning no vascular calcifications,
9:59
to grade 3, meaning severe or coarse vascular or tram track
10:02
calcifications affecting three or more vessels.
10:05
There's a little graph for us in the bottom right-hand corner.
10:09
There are many studies evaluating when we should be reporting these calcifications,
10:13
but generally, if you see moderate to severe calcifications in women under
10:17
60, it's worth reporting so that they can be assessed for cardiovascular risk
10:21
factors. There are even AI programs that have been developed or are
10:25
being developed to do this automatically, generating referrals to cardiology
10:29
for assessment.
10:33
Large rod-like calcifications, traditionally referred to as
10:37
secretory calcifications, are often associated with duct
10:40
ectasia or sequelae of plasma cell mastitis.
10:44
They're much more common in women over the age of 60, are often bilateral,
10:48
and follow a ductal distribution.
10:51
They often demonstrate branching as well.
10:54
Although these can be extremely easy to recognize, they can present some real
10:58
diagnostic dilemmas when initially forming, as they can be difficult to
11:01
distinguish from the highly suspicious fine linear branching pattern.
11:06
Seeing them develop bilaterally can help us distinguish them from their more
11:09
suspicious counterparts, although this is not a hard and fast rule as they can
11:13
still present unilaterally. Don't hesitate to recommend a biopsy
11:17
if you're not sure.
11:21
Coarse calcifications are now an extremely broad
11:24
category under the new BI-RADS atlas, now encompassing both
11:28
popcorn calcifications, which was a term traditionally used to describe
11:32
degenerating fibroadenomas, and dystrophic
11:35
calcifications, which are typically seen post-surgically.
11:40
This is one of the few changes regarding calcifications in BI-RADS 6.
11:45
These are large and conspicuous calcifications and are generally
11:48
greater than one millimeter and are dense and easily visualized.
11:52
They may be single or occur in clusters.
11:55
They're often associated with involuting fibroadenomas, fat
11:58
necrosis, prior surgery, trauma, or radiation therapy.
12:03
They have many different appearances, all of which we should recognize as benign.
12:07
They are not to be confused with coarse heterogeneous calcifications, which are
12:11
smaller and often vary in shape and size and will be discussed later
12:15
in detail.
12:19
Rim calcifications, sometimes referred to as eggshell or lucent
12:23
centered calcifications, are thin, benign calcifications that
12:27
appear as calcium deposited on the surface of a sphere.
12:30
They're often less than one millimeter in thickness when viewed on the
12:34
edge, and smooth in appearance.
12:37
These are often seen in fat necrosis, oil cysts, calcified
12:41
debris in ducts, or calcifications of cyst walls.
12:45
These often occur as sequelae to trauma, such as the example
12:48
provided here where a patient had a seatbelt injury from a motor vehicle
12:52
accident. The oil cysts can be seen traveling
12:56
horizontally down the breast in the expected pattern of the
12:59
seatbelt. The oil cysts and fat necrosis can sometimes be
13:03
difficult to diagnose on other modalities in breast imaging, such as MRI or
13:07
ultrasound. For example, at our institution, we perform what's called
13:11
fast breast MRIs, where we do not perform native T1
13:15
non-fat saturated sequences, making fat necrosis difficult to
13:18
distinguish from more concerning enhancement.
13:21
They can appear as shadowing masses on ultrasound as well.
13:24
If you suspect fat necrosis or oil cysts, mammography is always the
13:28
easiest modality to identify them and don't
13:31
hesitate to request additional mammographic imaging.
13:37
Layering calcifications are among the most satisfying imaging
13:41
diagnoses in mammography, in my opinion, due to their incredibly characteristic
13:45
appearance on spot magnification views.
13:48
These have been traditionally referred to as milk of calcium because their
13:51
appearance is a result of sedimented calcium layering into cysts and
13:55
acini. However, BI-RADS 6 makes clear that they do not
13:58
approve of any food-related nomenclature, waxing milk of
14:02
calcium and popcorn from our vocabulary.
14:05
On spot magnification CC views, they often appear as round and
14:09
smudgy. However, the key is that they change in appearance on lateral views
14:13
when gravity causes the calcium deposits to layer.
14:16
They form characteristic teacupping or crescent shapes on
14:19
mediolateral views, or sometimes just straight lines.
14:24
The key is that they have to change morphology on the orthogonal views.
14:29
Oftentimes, you will see diffuse layering calcifications, and some may
14:33
not layer. Be wary that suspicious calcifications can still
14:37
hide in a background of benign layering calcifications and
14:41
pay close attention that the vast majority of the calcifications are layering.
14:48
Round calcifications are one of the most common calcifications described on
14:52
diagnostic mammography. In the new BI-RADS atlas, round,
14:56
which was traditionally between 0.5 and one millimeter,
15:00
and punctate, which was traditionally round calcifications measuring less than
15:04
0.5 millimeters, have been lumped together due to the
15:07
impracticality of measuring individual calcifications.
15:11
Many of us have already been using them somewhat synonymously,
15:14
often reporting grouped round and punctate calcifications, so this is a
15:18
welcome simplification.
15:21
It is most important to assess the distribution and longitudinal
15:24
assessment of round calcifications.
15:28
Which brings us to BI-RADS 3. BI-RADS 3
15:32
is reserved for findings with a 2% or lower likelihood of
15:35
malignancy. For calcifications, the classic qualifying
15:39
finding is a single group of round calcifications discovered
15:43
on baseline mammography that has been evaluated with diagnostic
15:46
magnification views. These will be followed every six
15:50
months for two years to ensure that they remain stable, and the
15:54
18-month follow-up is often not necessary.
15:57
So it would be six months, six months, 12 months.
16:00
If any increase in the calcifications is visualized, these should be
16:03
biopsied.
16:06
Although this is the only true use case for BI-RADS 3 with
16:10
calcifications as defined by BI-RADS, I think anyone who's
16:13
engaged in breast imaging knows that this is often used much more
16:16
broadly. For example, in my own practice, I recently assigned a BI-RADS
16:21
3 to a case with regional amorphous calcifications that were likely
16:24
present on a prior exam, but so fine that it was nearly impossible to
16:28
tell. The key is to use your best judgment and try to assign
16:32
BI-RADS 3s as infrequently as possible.
16:35
The cost of three to four additional diagnostic mammograms can add
16:39
up extremely quickly for patients in cases where we could have just assigned a
16:43
BI-RADS 2. And in cases where a BI-RADS 3 was assigned and the
16:47
calcifications do increase and end up demonstrating malignancy, it's
16:51
important to know that it's still considered a false negative exam by BI-RADS
16:55
criteria and will not protect you from litigation if a BI-RADS 3 was
16:58
inappropriately assigned.
17:04
Here we have another image generated by
17:07
AI, but it provides a great
17:11
demonstration of the textbook baseline for the
17:15
old BI-RADS books and the new modern literature range
17:18
for concerning calcifications that can occur in the
17:22
breast.
17:24
For amorphous calcifications, it was traditionally thought to be a positive
17:27
predictive value of around 20%, which is now felt to be much lower.
17:32
For coarse heterogeneous calcifications, it was traditionally
17:36
thought to be around 15%, but now can be seen up to
17:40
30%.
17:42
Fine pleomorphic calcifications were only seen with a
17:46
positive predictive value of up to 30%, now up to almost
17:49
80%. And fine linear branching calcifications
17:54
have always thought to be suspicious, but are now seen to be
17:57
malignant in almost 100% of cases in some studies.
18:04
So let's begin with amorphous calcifications.
18:06
Amorphous calcifications are small and hazy and by definition cannot be
18:10
assigned a particular shape.
18:12
I know we're trying to wipe food analogies, but I often refer to their appearance
18:16
as powdered sugar. They encompass a wide variety of calcifications
18:20
overall, and therefore the distribution of calcifications and longitudinal
18:24
assessment as to whether they were new or increasing becomes extremely important.
18:29
I tried to use several different images to give a good demonstration of the
18:32
appearance of amorphous calcifications, and this is unfortunately the best I can
18:36
do. By their nature, they're going to be extremely difficult to
18:39
accurately visualize without full-scale mammography.
18:44
The distinction between coarse
18:48
heterogeneous calcifications and benign coarse calcifications is often
18:52
easy to describe in a book or lecture, but becomes very difficult in
18:56
practice.
18:57
By definition, compared to coarse calcifications, which are often over
19:01
two to three millimeters, coarse heterogeneous calcifications are
19:05
often half to a millimeter in size and are
19:09
irregular in shape. Distribution again becomes extremely
19:13
important in assessing concern, with grouped, linear,
19:16
segmental, or new and increasing calcifications warranting
19:20
biopsy.
19:21
It's not always cut and dry, unfortunately.
19:24
For example, in the case I've displayed here, although these calcifications
19:28
are diffuse, they ended up demonstrating LCIS and invasive lobular
19:31
carcinoma.
19:37
Fine pleomorphic calcifications are among the most suspicious morphology
19:41
and should almost always be immediately recognized and biopsied,
19:45
regardless of distribution. They consist of calcifications in
19:48
varying shapes and sizes, often referred to as a
19:52
dot-dash pattern like Morse code.
19:55
We can see the plethora of different morphologies within the grouping
19:59
demonstrated on the left in the CC and ML projections,
20:03
showing both linear, round, and irregular
20:06
calcifications.
20:08
Biopsy of these calcifications yielded ductal carcinoma in situ.
20:17
Fine linear and fine linear branching calcifications appear as thin,
20:21
linear, irregular calcifications which may be discontinuous and are
20:25
typically less than 0.5 millimeters in caliber.
20:28
Excuse me. Their appearance suggests filling of the lumen of the
20:32
ducts by breast cancer.
20:34
Again, these should almost always be immediately
20:38
recognized and biopsied, regardless of distribution, although they are
20:42
often in linear segmental distributions.
20:50
So that concludes the didactic portion of this lecture.
20:54
The remaining portion of the lecture is a few cases that I'd like to present to you
20:58
guys just to challenge what we've learned
21:01
and see if we have any questions about it.
21:08
And also, I apologize in advance. Again, without
21:11
full-field mammography monitors, a lot of these calcifications are
21:15
going to be difficult to identify.
21:18
So for case one, we have a screening mammogram, and we can
21:22
see calcifications kind of scattered around,
21:25
but there is a grouping of calcifications that we can see in the
21:29
central medial right breast at middle depth that appear
21:33
different than the rest of the calcifications.
21:35
Additional spot magnification views were recommended.
21:41
On additional spot magnification views, it's a bit difficult to see,
21:46
but there are linear branching calcifications
21:50
that are occurring in a Y-shaped pattern.
21:57
These were subsequently biopsied and demonstrated DCIS.
22:08
For our second patient,
22:10
calcifications were identified in the lateral central left
22:13
breast at middle depth.
22:17
On additional spot magnification views, we see that these calcifications
22:21
clearly layer on the orthogonal view and appear
22:25
smudgy and round on the CC
22:28
view. I'm sorry, I'm using my cursor in the wrong area.
22:31
Smudgy and round on the CC view
22:34
and demonstrate teacupping or layering on the ML view,
22:38
and so these are clearly benign milk of calcium.
22:49
For our third case, we have a grouping of calcifications that was
22:53
identified on screening mammography.
22:55
It's a bit harder to see. We're not really particularly interested in this dense
22:59
coarse calcification, but this small grouping of calcifications behind
23:03
it.
23:07
On additional spot magnification views, we see amorphous
23:11
grouped calcifications
23:14
corresponding to the calcifications initially seen on mammography.
23:18
These were biopsied and demonstrated atypia.
23:22
Atypical ductal hyperplasia, to be specific.
23:32
And here's a more zoomed-in photo to see that amorphous
23:36
morphology.
23:39
There's a few coarse calcifications also contained within
23:41
those.
23:45
But we always look at the most suspicious morphology of the
23:48
calcifications provided.
23:55
I'm not sure if we're able to go into the chat, but this is an Aunt
23:59
Minnie case, and I'm curious if anyone knows what this
24:02
is. But we see extensive rim
24:06
calcifications,
24:12
oil cysts,
24:18
Bourneville Pringle. I actually don't know what that is.
24:23
Siliconoma, oil cysts, fat injections. Yes.
24:26
So it's actually
24:28
pathognomonic for free silicone injections.
24:32
This is something that was done in
24:35
Way back in the '70s, '80s, as an alternative to breast
24:39
augmentation.
24:41
And this patient actually presented to me,
24:44
it was a transgender male transitioning to female
24:48
patient
24:50
that had had free silicone injections to
24:53
increase his breast size and had gotten them on
24:57
the black market. I had never seen a case
25:02
in real life before this, but it was extremely interesting.
25:05
I felt terrible for the patient. He was having, or she, excuse me, she was having
25:09
so much pain
25:11
in both the breasts and the axillas from
25:14
the silicone traveling into the lymph nodes and
25:18
causing silicone granulomas.
25:22
So silicone would be injected directly into the breast tissue without
25:25
being contained in a shell and would disperse into the breast and surrounding
25:29
tissues. This could cause many long-term issues due to the formation of silicone
25:33
granulomas, and the lymph nodes become hard and painful.
25:36
Although the free silicone is not linked to a direct increase in breast
25:39
cancer, it does make future screening extremely difficult.
25:43
Like free silicone elsewhere, this generates a characteristic snow storm
25:47
appearance on the ultrasound.
25:56
For our next case, we have grouped calcifications
26:00
that were identified in the superior, slightly medial left breast
26:04
on screening mammography.
26:11
On additional spot magnification views, we see both
26:15
coarse heterogeneous and possibly some linear branching
26:18
patterns of these calcifications.
26:22
These ended up being DCIS with a
26:26
microinvasive component.
26:32
Here we just see a typical demonstration of large
26:36
coarse benign calcifications for which no additional
26:40
imaging is necessary.
26:47
So
26:49
this case was initially identified on screening
26:53
mammogram and spot magnification views
26:56
demonstrated some coarse and round grouped calcifications
27:00
in the upper outer left breast.
27:02
They were initially given an assessment of a BI-RADS 3 appropriately,
27:07
and the patient returned for follow-up.
27:11
On follow-up imaging, we can see that there's an increase in those
27:15
calcifications.
27:19
This was subsequently assigned a BI-RADS 4 and
27:23
biopsied and demonstrated ductal carcinoma in
27:25
situ. This is a great example of how
27:29
longitudinal management can be helpful in assessment.
27:37
Next, we have a screening mammogram of the left breast demonstrating
27:40
calcifications in the upper outer left breast at
27:44
anterior depth,
27:46
for which additional spot magnification views were recommended.
27:53
On additional spot magnification views, we see a clear linear
27:57
branching pattern and a segmental distribution indicating a
28:00
highly suspicious finding.
28:05
These were biopsied and demonstrated
28:07
DCIS. I think an interesting
28:12
note that I can make here too is there's a lot of
28:15
discussion around when we should perform just one biopsy of the
28:19
calcifications versus two biopsies to demark the
28:23
anterior and posterior extent of disease and calcifications.
28:28
There's no set hard and fast rules.
28:31
Our institution uses about four centimeters of
28:34
calcifications.
28:37
If there's more than four centimeters of calcifications, it may be more worthwhile
28:42
to do two biopsies, one at the anterior and one at the
28:46
posterior aspect of the calcifications.
28:49
This can make things easier to localize in the future and can help determine the
28:53
extent of disease.
28:55
Anytime you have a large grouping of calcifications and there's more than one
28:59
different type of morphology of calcifications that you see within those
29:03
groupings,
29:04
you should biopsy multiple, excuse me, you should biopsy each
29:08
of the different morphologies to make sure that we're
29:11
not getting a benign result at one where one might be
29:15
malignant.
29:20
For this next case,
29:22
the calcifications are difficult to identify here just because of the quality of
29:25
the images, but there are calcifications in the upper inner left
29:29
breast at posterior depth.
29:33
On additional spot magnification views,
29:36
we see grouped kind of coarse heterogeneous calcifications,
29:40
and on the CC view, they appear to be in a linear pattern.
29:45
These were suspicious and biopsied and demonstrated
29:49
DCIS.
29:54
And finally, for our last case, we have calcifications that were
29:58
identified in the upper outer left breast at
30:02
middle to posterior depth,
30:04
for which additional spot magnification views were performed.
30:09
And I apologize, I lost the spot magnification views on those,
30:14
but they did demonstrate calcifications in a segmental pattern, which is what
30:18
I was trying to demonstrate here, and you can see how it's kind of a
30:21
pizza pie shape
30:24
projecting from the nipple.
30:28
Although we're not using food terminology anymore, I know, I'm sorry.
30:32
And these were highly suspicious and demonstrated DCIS with
30:35
an invasive component
30:39
And last, I just have our little frowny face of calcifications
30:43
I biopsied because they were upset with me.
30:47
No, I'm just kidding. These were benign. Thank you guys so much.
30:52
I'll take any questions.
30:57
Awesome. Thank you so much. I do see one question in the Q&A feature, and just want
31:01
to direct all other questions over there if anyone else has any other
31:05
ones.
31:06
Thank you so much. "Is the spot view on the CC projection
31:10
necessary to evaluate microcalcifications, or is a true lateral
31:14
view sufficient?" Spot CC views are absolutely
31:18
necessary in evaluating microcalcifications.
31:21
Seeing the calcifications in two orthogonal planes
31:24
makes a world of difference in assessing the morphology
31:28
and the distribution of these calcifications.
31:31
For example,
31:33
for these calcifications, I don't have the spot magnification views,
31:37
but they didn't appear quite as segmental or
31:40
concerning in the CC view, but they definitely appear
31:44
segmental and concerning on the ML view.
31:47
And it's always necessary to have them both.
31:52
"Can I recommend any good articles regarding this?"
31:56
I would recommend looking through the BI-RADS atlas.
31:59
I have not seen any good review articles recently on
32:03
calcifications, but mostly probably because I wasn't looking, and I
32:07
apologize for that. "To what extent of the
32:11
calcifications in your practice to suggest mastectomy?" So that is
32:15
a great question.
32:19
That is determined by the surgeon and the patient.
32:23
We can suggest a mastectomy, but it is an
32:26
extremely fluid conversation, depending on the size of
32:30
the breast, especially. So let's say we have about four
32:34
centimeters of calcifications. I believe the traditional thinking was greater
32:38
than five centimeters or so of disease, you should do a
32:41
mastectomy. But, if a woman has extremely
32:45
large breasts, five centimeters of disease may
32:49
not be that much disease in relation to the size of her
32:53
breast. They may be able to do a lumpectomy, and you might not even
32:56
notice a change in the size of the breast.
33:00
So there is actually no hard and fast rule regarding when a
33:03
mastectomy needs to be performed, and that will always just be a
33:07
discussion between the surgeon and the patient.
33:10
We have a great relationship with our surgeons here at University Hospital, and
33:13
we often are in discussions all the time with them as to
33:17
whether we feel the patient may need a mastectomy based on the imaging
33:21
features. There's a lot that goes into that in terms of,
33:25
can we appropriately bracket this in two planes
33:30
in order to remove the extent of the disease?
33:33
And sometimes it's not possible. Sometimes there's just such a
33:37
wide margin of disease, it's not just
33:41
localized to this kind of segmental pattern, that you would have to
33:45
do a whole quadrantectomy, in which case you should just probably do a
33:48
mastectomy. And sometimes it's an extremely long length of
33:52
disease, but it's very narrow and
33:56
can be done with bracketing. So there's really just no hard and fast rule
34:00
there.
34:01
And I'm going to go through these in order.
34:04
I'm going to start with the Q&A box.
34:07
"Amorphous versus round and punctate is confusing.
34:09
Can you please clarify?" So if you can see, and I completely agree by the
34:13
way,
34:15
if you can see a well-defined
34:19
borders to these calcifications, oftentimes you can call
34:23
them round and punctate.
34:25
The amorphous calcifications, it's very hard to describe because
34:29
they, by definition, don't have a shape. They're indistinct.
34:33
You can't really identify an exact shape.
34:36
They just kind of look like you sprinkled something on the breast
34:39
there. A lot of times, they're extremely difficult to identify on the screening
34:43
mammography itself, and sometimes they don't even appear until you get those
34:47
spot magnification views.
34:49
But that is a great question, and I wish I had a better answer for that.
34:54
"We biopsy calcifications scored M3 and over
34:58
in the UK."
35:00
I sincerely apologize. I don't know what the M3
35:04
scoring is in reference to, if you don't mind clarifying
35:07
that.
35:09
"Do we do ultrasound-guided biopsy of suspicious calcifications?"
35:14
Typically not.
35:16
If there's an associated mass or architectural
35:19
distortion or ultrasound finding that is seen in
35:22
conjunction with the calcifications, absolutely, you can
35:27
biopsy those on ultrasound. And oftentimes what I do in those cases
35:31
is I'll use a vacuum-assisted device, and then I will X-ray the
35:35
specimen to ensure I got some calcifications in that specimen.
35:39
But isolated calcifications, I will practically never
35:43
biopsy by ultrasound alone. They should always be done
35:47
using stereotactic biopsy.
35:51
"Do you think follow-up should be done in a case of even slightly
35:55
suspicious calcification in the case you showed us, which turned out to
35:59
be malignant?"
36:02
We could have just gone straight to biopsy on that case.
36:05
It was a baseline, and I believe she did have calcifications
36:09
scattered throughout both breasts, and so those didn't look
36:12
as concerning in the larger clinical picture, but it would not have
36:16
been inappropriate to biopsy in that situation.
36:20
With calcifications, it's one of the things in
36:23
mammography that always surprises me.
36:26
There are so many times where looking at the diagnostic
36:30
imaging, I've been certain that calcifications would come out benign,
36:34
and they've demonstrated some sort of atypical or early
36:37
malignant pathology, and that's just kind of how it goes, unfortunately.
36:41
We follow the BI-RADS atlas and do the best we can in those
36:45
cases.
36:48
What information do surgeons ask for before performing a mastectomy,
36:52
specifically regarding the size of the microcalcification
36:55
areas? That's particularly the first one is, what is the
36:59
extent? And you want to identify that extent in all three
37:03
planes, if possible.
37:05
Transverse, craniocaudal, and,
37:10
excuse me, why am I blanking? APTR and CC,
37:13
sorry. On top of that,
37:16
it also depends if the surgeon is interested in getting an MRI for
37:20
extent of disease. The MRIs for extent of disease in
37:24
the case of calcifications is-- or excuse me, in the case of DCIS
37:28
specifically, which is typically from calcifications, is somewhat
37:31
controversial, just because
37:35
early-grade DCIS does not have to enhance on
37:38
MRI,
37:40
and so sometimes it may not be the best form of
37:44
extent of disease management. However, that's pretty rare in my
37:48
practice. Almost always, if we see DCIS on a mammogram
37:52
that was biopsied and we get an MRI, it almost always enhances.
37:56
The other things that we're looking at when we're evaluating the extent of disease,
38:00
is there any involvement of the chest wall?
38:04
How close does it come to the chest wall or pectoralis muscle?
38:07
How close does it come to the skin? And then how close does it come to the nipple?
38:11
And that can even be important in evaluating if a patient
38:15
needs a nipple-sparing versus radical mastectomy.
38:19
Excuse me, not radical, but non-nipple-sparing mastectomy.
38:24
And so if those calcifications are within one to two centimeters, and I think
38:28
the criteria has changed of the surgeons as to what the exact
38:32
measurement is within the nipple.
38:34
As long as it's not closer
38:38
than one to two centimeters from the nipple, oftentimes they can spare the
38:42
nipple.
38:45
M3 is the same as BI-RADS 3. Thank you so much.
38:47
So let me go back to your questions.
38:49
We biopsy calcifications scored
38:52
BI-RADS 3 and over in the UK. Our practice is to follow anything
38:56
that's given a BI-RADS 3. If we feel that they need to
39:00
be biopsied, if we feel the calcifications need to be biopsied, we go
39:04
directly to what you might consider an M4 or a BI-RADS 4 for
39:07
us.
39:10
Is abscess still given a BI-RADS
39:14
4a? I'm not 100% sure.
39:19
I've seen kind of varying thoughts on that.
39:22
Typically, I give, if I'm 100% certain it's an abscess, I give it a
39:26
BI-RADS 2 every time for benign, and I recommend drainage and
39:29
antibiotics. But if it's not certain that it's an
39:33
abscess, if you're not 100% certain, then I do assign a BI-RADS 4,
39:38
and then I request follow-up imaging after
39:42
treatment to see if that area has resolved.
39:46
If that area has not resolved, I keep it a four, and I recommend
39:50
an ultrasound-guided biopsy, and if it has
39:53
resolved,
39:55
then I just change it to a two. We're very lucky in our
39:58
practice. We have our clinical practitioners that see patients for us
40:02
directly when they're having their imaging if needed, and so
40:06
it's much easier to come up with a game plan
40:11
when the patient's being seen right there in clinic for their abscess,
40:15
just as they're getting their imaging.
40:17
And then, I'm sorry, I'm going to scroll back up
40:20
here.
40:26
In the BI-RADS 3 case, would it have helped to perform
40:29
contrast-enhanced mammography?
40:33
So we only recommend contrast-enhanced mammography in very
40:37
specific situations. Typically, for high-risk
40:40
screening for individuals who can't have an MRI,
40:46
or for extent of disease and evaluation for patients who can't undergo
40:50
MRI. In calcifications, I've never
40:54
seen contrast-enhanced mammography
40:57
ordered for the assessment of calcifications.
40:59
I don't think that there are any studies demonstrating
41:03
a benefit to that, but someone else may be more knowledgeable about that.
41:09
Will AI and improved workstation monitors eventually decrease
41:13
the amount of follow-ups on additional mammographic imaging?
41:17
I certainly hope so. I'm not sure how
41:20
much better the monitors can really get.
41:24
But AI, I think, will help
41:28
in reducing the number of callbacks, to be clear, because I
41:32
think,
41:33
in the AI studies that I've read, one of the biggest things is they
41:37
can help identify a negative case.
41:40
So if the AI identifies nothing of concern on the
41:44
case, there's a very high predictive value that it's
41:48
correct.
41:49
But it has a really hard time identifying, or
41:53
not a really hard time, but it has a harder time identifying positive things.
41:57
So if you do have things that marked, it does not mean that that thing is
42:00
suspicious.
42:02
You still need to review, if you have an AI program.
42:05
We do not have an AI program established with our mammography yet.
42:09
But if you do, you should kind of treat it like CAD.
42:12
It's directing your attention to certain areas, and
42:16
you are going to evaluate with your knowledge and expertise,
42:20
what you see at that area. Does fine-needle
42:24
aspiration biopsy have a role, or is it just core biopsy for more
42:28
samples? We do not perform fine-needle aspirations,
42:33
typically, only in very select cases.
42:36
Almost always, we're performing core biopsies.
42:39
I think that's the standard
42:42
for most institutions these days.
42:48
Does contrast-enhanced mammography show microcalcifications?
42:51
Absolutely it does, because-
42:55
Typically, 2D images are created which will demonstrate the
42:58
microcalcifications, as well as the contrast-enhanced images.
43:03
They have to do both to create a subtraction in the same way that
43:06
you would do pre- and post-contrast MRIs.
43:10
And so, yes, you would see the microcalcifications.
43:12
You would not see them in good detail because you need those spot magnification
43:16
views. And so let's say you had a patient being screened with
43:19
contrast-enhanced mammography.
43:22
I believe, and I'm not 100% certain on this, but I'm almost certain, the
43:25
recommendation is that they still get a typical screening mammogram, whether it's
43:29
2D or tomosynthesis. So the calcifications are probably going to be much better
43:33
identified there anyways,
43:36
but you would still be able to see them on the CEM.
43:42
Microcalcifications with lucent center should almost always be a BI-RADS
43:46
2. Sometimes in very rare circumstances,
43:50
depending on a distribution and whether they're increasing, it's hard to say that
43:54
that's 100%, but almost always lucent
43:58
centered calcifications will be a BI-RADS 2 benign.
44:01
I'm going to move over to the chat because I think people asked some questions in
44:05
here, too.
44:10
Okay. I think we answered that one already.
44:16
Do you advise MR for suspicious calcifications?
44:19
No, I would recommend that you never advise MR for
44:23
suspicious calcifications. I think I briefly touched on it, but
44:27
low-grade DCIS does not necessarily enhance on MRI, and
44:31
therefore you're actually doing the patient a disservice by recommending
44:35
an MRI for calcifications. The recommendation should always
44:39
be diagnostic mammography with spot magnification views.
44:43
It's actually something that we've struggled with in our
44:47
practice recently, is we will recall patients from
44:51
mammography, for additional mammographic and sonographic
44:54
views, and their providers
44:59
just kind of expect that MRI is the best test, and so
45:02
sometimes they'll kind of ignore those recommendations and just skip straight to
45:06
MRI.
45:08
And it is extremely challenging,
45:13
because a lot of times the best test would've just been that
45:17
diagnostic mammography and ultrasound, and then you're kind
45:20
of stuck in this position of backtracking, trying to
45:24
associate the findings that you initially saw on the
45:27
screening mammogram,
45:31
and it's just something that I would never recommend.
45:36
And let's see. BI-RADS 3, how concerning is
45:40
it? Is there a possibility of it turning into cancer, especially if the
45:44
patient's breast showed dense breast tissue?
45:47
So our studies within breast imaging show
45:50
that you shouldn't really be giving a BI-RADS 2 unless it's less than a 2% chance
45:54
of breast cancer. So you have to think it's between a zero and 2% chance that it'll
45:58
develop into cancer if it's a BI-RADS 3.
46:02
Sometimes patients will request to just have those biopsied because they
46:06
don't want to sit and be anxious for two years, and I totally respect
46:09
that. The fact that they have
46:13
dense breast tissue shouldn't play a factor in the
46:17
calcifications themselves, although dense breast tissue is
46:20
independently a risk factor for developing breast cancer.
46:25
Is vacuum biopsy acceptable to biopsy segmental
46:29
calc or stereo always? If there's an
46:32
associated ultrasound finding, such as a mass
46:36
on the ultrasound, it's totally fine to do it under
46:39
ultrasound.
46:41
If you can clearly see the calcifications under
46:45
ultrasound and you want to attempt an ultrasound-guided biopsy because the patient
46:48
can't have a stereotactic biopsy, that may not be
46:52
inappropriate. But if you have the capability of doing a stereotactic biopsy and
46:56
you're looking at calcifications and there's no associated ultrasound finding
46:59
besides those
47:02
fine echogenic foci on the ultrasound, I
47:05
would say just always do a stereotactic biopsy.
47:09
That would be the recommendation.
47:15
What would be the number of calcifications needed in
47:19
a new cluster for biopsy? Can we biopsy if the number is less than five?
47:23
I'm not 100% sure about the number that you would need in a
47:27
new cluster for biopsy. I've done it in
47:31
cases of three or less that were oriented in a linear pattern, and
47:35
they came out DCIS. So I don't think there's an exact
47:38
number. Obviously, if it's one singular calcification,
47:43
I think
47:44
that would be an easy one not to biopsy,
47:46
but anything like two, three, or more, it's not
47:50
unreasonable if the morphology is suspicious or the distribution is
47:54
suspicious.
47:58
How many calcifications in the sample need to be
48:01
representative for calcifications?
48:04
So I assume that's
48:05
in respect to if you're doing a stereotactic
48:09
biopsy and you image the specimen,
48:13
how many calcifications do we need to see within that specimen?
48:18
Sometimes I've only gotten one or two calcifications in
48:22
what looked like a larger grouping, and I've been able to make a diagnosis, and
48:26
sometimes I've gotten more than that, and they haven't identified
48:30
any calcifications in the pathology sample.
48:33
I think the real answer is just as many as you can get.
48:37
If you only have one or two, it's going to be much harder for that
48:41
pathologist to make a diagnosis. There's a chance that the slices that they cut
48:45
through your specimen don't contain those one or two calcifications.
48:49
So really, the answer is just get as many as you can
48:53
without causing undue harm to the patient,
48:56
and hope for the best.
49:00
"What BI-RADS score do you assign if you have MRI lesion
49:03
BI-RADS 2, but no mammography was
49:07
performed as the patient does not want?"
49:10
It's kind of a decision based on you and your group
49:14
and your institution.
49:18
You're supposed to really just recommend the
49:22
BI-RADS score based on the imaging that you're looking at.
49:25
So if it's a negative MRI, you should just give it a
49:29
BI-RADS 2 or BI-RADS 1, and then say, "This patient is
49:33
due for annual screening, and we recommend annual screening." Some patients just
49:37
won't do the screening, and I don't think it's appropriate to just keep giving them
49:41
zeros over and over again for every one of their exams.
49:45
There are patients who just can't undergo mammography due to certain
49:49
reasons. And so, you should just assign the BI-RADS
49:53
category based on the imaging that you're looking at, and then make that additional
49:56
recommendation. My tagline that I always use
50:00
is
50:04
basically, "MRI is not a
50:09
replacement for mammography, and mammography should still be performed
50:13
if possible."
50:14
Because it's not a replacement for mammography, because of exactly what we're
50:17
talking about in regards to low-grade DCIS, which can
50:21
be diagnosed mammographically, but not on MRI.
50:27
"Can MRI be done to look for the extent of
50:31
invasive disease in biopsy-proven
50:35
B5b microcalcifications?" I'm so sorry.
50:38
I don't know what B5b is. But absolutely, MRI can be
50:42
done to evaluate the extent of disease
50:46
in any microcalcifications that came back cancerous.
50:51
So even if you do a biopsy and the patient
50:55
has atypia on pathology,
50:59
that patient's now high risk, and so they qualify for
51:03
screening MRI,
51:05
even if it's not necessarily a, quote-unquote, "extent of disease
51:09
MRI." So you can definitely, with any sort of
51:13
positive finding on a biopsy of calcifications, you can
51:16
justify an MRI in some regards. Is it always the best choice?
51:20
Maybe, and maybe not.
51:23
In cases of atypia or high-risk lesions that
51:26
we're finding from calcifications, it typically is a very good
51:30
choice to get additional screening with MRI because their risk is going to be so
51:34
high.
51:36
But
51:39
I lost my train of thought there. I apologize.
51:41
But
51:43
it can definitely be done to evaluate for extent of
51:46
disease.
51:51
And then let me see
51:54
if there's anything else here. "Post-operative
51:58
scar with lucent center developing centrally
52:02
microcalcifications."
52:05
Post-operative scar with lucent center developing
52:09
centrally microcalcifications.
52:14
I think what you might be referring to in some cases would be
52:18
fat necrosis occurring at a post-operative scar.
52:21
That's where a lot of times we see the oil cysts forming with lucent
52:25
centers.
52:26
And actually, I had a case which I did not include in my
52:30
presentation today, but I think I actually have it
52:34
open on my computer somewhere if I look really quickly.
52:39
Let me see real quick. But I did have a case where a patient had
52:43
lucent centered calcifications at a lumpectomy bed, and they developed new
52:47
calcifications
52:49
right in line with those lucent centered
52:51
calcifications. Those calcifications looked a little bit more coarse,
52:55
heterogeneous, amorphous. We biopsied them, and it did end up being a
52:59
recurrence. It's not always the case.
53:02
Sometimes it's just developing fat necrosis at a post-surgical
53:05
site. But you kind of have to just take all the factors into account.
53:10
If the patient had a lumpectomy because they had cancer that presented as
53:14
calcifications at that lumpectomy site, you need to
53:18
be very cautious about the calcifications that you're going to
53:21
follow or call benign as opposed to biopsy at that site, because there's a very
53:25
high risk of recurrence occurring as calcifications at that site.
53:29
Does that answer your question? I apologize.
53:31
I wasn't 100% sure what you're asking.
53:36
I'm always happy to take questions offline as well.
53:40
You are always welcome to email me at
53:42
omar.nemer@uhhospitals.org.
53:46
It was such a pleasure giving this talk for you all.
53:49
Thank you guys all for the words of encouragement.
53:52
I hope you guys enjoyed it. I hope you guys all learned something, and I really
53:55
appreciate you guys having me.
53:58
Awesome. Thank you for sharing that lecture with us today, Dr.
54:01
Nemer. Be sure to join us next week
54:05
on Thursday, July 23rd at 12:00 p.m., where
54:09
Dr. Suresh Mukherjee will deliver a lecture entitled "Emergency Head and
54:13
Neck: What You Need to Know in the Middle of the Night." You can register for that
54:17
at modality.com and follow us on social media for updates on future
54:20
noon conferences. Thanks again, and have a great day.